Effect of macitentan on hospitalizations: Results from the SERAPHIN trial

JACC: Heart Failure

Volumn 3, Issue 1, 2015, Pages 1-8

  Channick, Richard N ^a   Delcroix, Marion ^b   Ghofrani, Hossein Ardeschir ^c,d   Hunsche, Elke ^e   Jansa, Pavel ^f   Le Brun, Franck Olivier ^e   Mehta, Sanjay ^g   Pulido, Tomás ^h   Rubin, Lewis J ⁱ   Sastry, B K S ^j   Simonneau, Gérald ^k,l,m   Sitbon, Olivier ^k,l,m   Souza, Rogério ⁿ   Torbicki, Adam ^o   Galiè, Nazzareno ^p  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ACTELION PHARMACEUTICALS LTD   (Switzerland)

^f CHARLES UNIVERSITY   (Czech Republic)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h Ignacio Chavez National Heart Institute   (Mexico)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j CARE HOSPITAL   (India)

^k BICÊTRE HOSPITAL   (France)

^l UNIVERSITÉ PARIS SACLAY   (France)

^m CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

ⁿ UNIVERSITY OF SÃO PAULO   (Brazil)

^o Medical Center of Postgraduate Education   (Poland)

^p UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

Hospitalization; Macitentan; Pulmonary arterial hypertension

Indexed keywords

MACITENTAN; PLACEBO; ENDOTHELIN A RECEPTOR ANTAGONIST; PYRIMIDINE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BRONCHITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEART RIGHT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; MULTICENTER STUDY; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SYMPTOMATOLOGY; UPPER RESPIRATORY TRACT INFECTION; AGED; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECTS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; LUNG WEDGE PRESSURE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME; TRENDS;

ADMINISTRATION, ORAL; ADULT; AGED; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENDOTHELIN A RECEPTOR ANTAGONISTS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PULMONARY WEDGE PRESSURE; PYRIMIDINES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84920263628     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.07.013     Document Type: Article

References (26)

1. Galiè N., Hoeper M.M., Humbert M., et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009, 30:2493-2497.
2. Humbert M., Sitbon O., Chaouat A., et al. Survivalin patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010, 122:156-163.
3. Condliffe R., Kiely D.G., Peacock A.J., et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009, 179:151-157.
4. Benza R.L., Miller D.P., Barst R.J., Badesch D.B., Frost A.E., McGoon M.D. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142:448-456.
5. Galiè N., Simonneau G., Barst R.J., Badesch D., Rubin L. Clinical worsening in trials of pulmonaryarterial hypertension: results and implications. Curr Opin Pulm Med 2010, 16(Suppl 1):S11-S19.
6. Kirson N.Y., Birnbaum H.G., Ivanova J.I., Waldman T., Joish V., Williamson T. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population. Appl Health Econ Health Policy 2011, 9:293-303.
7. Burger C.D., Long P.K., Shah M.R., et al. Characterization of first-time hospitalizations in patients with newly diagnosed pulmonary arterial hypertension in the REVEAL registry. Chest 2014, 146:1263-1273.
8. Simonneau G., Rubin L.J., Galiè N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
9. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost toexisting bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
10. Barst R.J., Oudiz R.J., Beardsworth A., et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. JHeart Lung Transplant 2011, 30:632-643.
11. McLaughlin V.V., Benza R.L., Rubin L.J., et al. Addition of inhaled treprostinil to oral therapy forpulmonary arterial hypertension: a randomized controlled clinical trial. JAm Coll Cardiol 2010, 55:1915-1922.
12. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. NEngl J Med 2002, 346:896-903.
13. Galiè N., Rubin L., Hoeper M., et al. Treatment ofpatients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008, 371:2093-2100.
14. Barst R.J., Langleben D., Badesch D., et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. JAm Coll Cardiol 2006, 47:2049-2056.
15. Galiè N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019.
16. Ghofrani H.A., Galiè N., Grimminger F., et al. Riociguat for the treatment of pulmonary arterialhypertension. NEngl J Med 2013, 369:330-340.
17. Gatfield J., Grandjean C.M., Sasse T., Clozel M., Nayler O. Slow receptor dissociation kinetics differentiate macitentan from other endothelinreceptor antagonists in pulmonary arterial smooth muscle cells. PLoS One 2012, 7:e47662.
18. Iglarz M., Binkert C., Morrison K., et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. JPharmacol Exp Ther 2008, 327:736-745.
19. Pulido T., Adzerikho I., Channick R.N., et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. NEngl J Med 2013, 369:809-818.
20. Cuzick J. Forest plots and the interpretation of subgroups. Lancet 2005, 365:1308.
21. Heilbron D.C. Zero-altered and other regression models for count data with added zeros. Biom J 1994, 36:531-547.
22. McLaughlin V.V., McGoon M.D. Pulmonary arterial hypertension. Circulation 2006, 114:1417-1431.
23. Galiè N., Manes A., Negro L., Palazzini M., Bacchi-Reggiani M.L., Branzi A. Ameta-analysis of randomized controlled trials in pulmonary arterialhypertension. Eur Heart J 2009, 30:394-403.
24. Galiè N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. NEngl J Med 2005, 353:2148-2157.
25. McLaughlin V.V., Badesch D.B., Delcroix M., et al. End points and clinical trial design in pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54:S97-S107.
26. Fleming T.R., Powers J.H. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012, 31:2973-2984.